Physician profile
David A Fields
NPI 1013094184
$6,437.62
in general payments reported to CMS, 2019-2025
38 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $341 · 2021: $2,470 · 2022: $578 · 2023: $901 · 2024: $818 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.34 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,221.15 | 2021 | |
| Novo Nordisk INC | $698.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $412.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Medtronic, INC. | $360.34 | 2023-2025 | Minimed 780g, Minimed 770g |
| Glaxosmithkline, LLC. | $279.16 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $213.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.79 | 2019-2025 | Jardiance, Tradjenta |
| Zyla Life Sciences, INC. | $177.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.75 | 2021-2024 | |
| Indivior INC. | $125.00 | 2023 | Perseris |
| Otsuka America Pharmaceutical, INC. | $120.50 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $116.90 | 2019-2023 | Spravato, Xarelto |
| Allergan, INC. | $101.74 | 2019-2020 | |
| Pfizer INC. | $93.22 | 2019-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.